These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 30893157)

  • 1. Ten-Year and Beyond Follow-up After Treatment With Highly Purified Liquid-Injectable Silicone for HIV-Associated Facial Lipoatrophy: A Report of 164 Patients.
    Jones DH; Carruthers A; Brody HJ; Black JM; Humphrey S; Carruthers J; Wesley NO; Minokadeh A
    Dermatol Surg; 2019 Jul; 45(7):941-948. PubMed ID: 30893157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A case of HIV-associated facial lipoatrophy treated with 1000-cs liquid injectable silicone.
    Orentreich D; Leone AS
    Dermatol Surg; 2004 Apr; 30(4 Pt 1):548-51. PubMed ID: 15056149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV-associated facial lipoatrophy treated with injectable silicone oil: a pilot study.
    Chen F; Carruthers A; Humphrey S; Carruthers J
    J Am Acad Dermatol; 2013 Sep; 69(3):431-7. PubMed ID: 23711767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Highly purified 1000-cSt silicone oil for treatment of human immunodeficiency virus-associated facial lipoatrophy: an open pilot trial.
    Jones DH; Carruthers A; Orentreich D; Brody HJ; Lai MY; Azen S; Van Dyke GS
    Dermatol Surg; 2004 Oct; 30(10):1279-86. PubMed ID: 15458523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liquid injectable silicone for soft tissue augmentation.
    Prather CL; Jones DH
    Dermatol Ther; 2006; 19(3):159-68. PubMed ID: 16784515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retreatment with injectable poly-l-lactic acid for HIV-associated facial lipoatrophy: 24-month extension of the Blue Pacific study.
    Mest DR; Humble GM
    Dermatol Surg; 2009 Feb; 35 Suppl 1():350-9. PubMed ID: 19207325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Polylactic acid injections: usefullness for the treatment of facial lipoatrophy in HIV+ patients under tritherapy].
    Piquet M; Brignol L; Chatelain B; Rey D; Ricbourg B; Meyer C
    Rev Stomatol Chir Maxillofac; 2007 Dec; 108(6):496-504. PubMed ID: 17675198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV facial lipoatrophy: causes and treatment options.
    Jones D
    Dermatol Surg; 2005 Nov; 31(11 Pt 2):1519-29; discussion 1529. PubMed ID: 16416634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of the safety and efficacy of poly-L-lactic acid for the treatment of HIV-associated facial lipoatrophy.
    Burgess CM; Quiroga RM
    J Am Acad Dermatol; 2005 Feb; 52(2):233-9. PubMed ID: 15692467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Semipermanent filler treatment of HIV-positive patients with facial lipoatrophy: long-term follow-up evaluating MR imaging and quality of life.
    van Rozelaar L; Kadouch JA; Duyndam DA; Nieuwkerk PT; Lutgendorff F; Karim RB
    Aesthet Surg J; 2014 Jan; 34(1):118-32. PubMed ID: 24334306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term safety and efficacy of poly-L-lactic acid in the treatment of HIV-related facial lipoatrophy.
    Moyle GJ; Brown S; Lysakova L; Barton SE
    HIV Med; 2006 Apr; 7(3):181-5. PubMed ID: 16494632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liquid injectable silicone: a review of its history, immunology, technical considerations, complications, and potential.
    Narins RS; Beer K
    Plast Reconstr Surg; 2006 Sep; 118(3 Suppl):77S-84S. PubMed ID: 16936547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and Efficacy of a Volumizing Hyaluronic Acid Filler for Treatment of HIV-Associated Facial Lipoatrophy.
    Ho D; Jagdeo J
    JAMA Dermatol; 2017 Jan; 153(1):61-65. PubMed ID: 27806168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective, open-label, 18-month trial of calcium hydroxylapatite (Radiesse) for facial soft-tissue augmentation in patients with human immunodeficiency virus-associated lipoatrophy: one-year durability.
    Silvers SL; Eviatar JA; Echavez MI; Pappas AL
    Plast Reconstr Surg; 2006 Sep; 118(3 Suppl):34S-45S. PubMed ID: 16936543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of complications of injectable silicone.
    Hexsel D; de Morais MR
    Facial Plast Surg; 2014 Dec; 30(6):623-7. PubMed ID: 25536128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A systematic review of permanent and semipermanent dermal fillers for HIV-associated facial lipoatrophy.
    Sturm LP; Cooter RD; Mutimer KL; Graham JC; Maddern GJ
    AIDS Patient Care STDS; 2009 Sep; 23(9):699-714. PubMed ID: 19673594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Commentary on Ten Year Follow Up After Treatment With Highly Purified Liquid Injectable Silicone for HIV Facial Lipoatrophy.
    Mandy S
    Dermatol Surg; 2019 Jul; 45(7):949. PubMed ID: 30789525
    [No Abstract]   [Full Text] [Related]  

  • 18. Four-year safety with polyacrylamide hydrogel to correct antiretroviral-related facial lipoatrophy.
    Negredo E; Puig J; Aldea D; Medina M; Estany C; Pérez-Alvarez N; Rodríguez-Fumaz C; Muñoz-Moreno JA; Higueras C; Gonzalez-Mestre V; Clotet B
    AIDS Res Hum Retroviruses; 2009 Apr; 25(4):451-5. PubMed ID: 19320569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of poly-L-lactic acid injections in persons with HIV-associated lipoatrophy: the US experience.
    Mest DR; Humble G
    Dermatol Surg; 2006 Nov; 32(11):1336-45. PubMed ID: 17083585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hyaluronic acid new formulation: experience in HIV-associated facial lipoatrophy.
    Bechara FG; Gambichler T; Brockmeyer NH; Sand M; Altmeyer P; Hoffmann K
    Dermatology; 2008; 217(3):244-9. PubMed ID: 18663308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.